PMID- 17920287
OWN - NLM
STAT- MEDLINE
DCOM- 20080325
LR  - 20071206
IS  - 1096-0023 (Electronic)
IS  - 1043-4666 (Linking)
VI  - 40
IP  - 2
DP  - 2007 Nov
TI  - Different effect of unfractionated heparin and enoxaparin on circulating 
      proangiogenic factors during hemodialysis: A cross-over study.
PG  - 98-104
AB  - BACKGROUND: We aimed to compare the effect of unfractionated heparin (UFH) and 
      enoxaparin used as anticoagulants during hemodialysis (HD) on circulating levels 
      of heparin-binding, endothelial-derived, proangiogenic factors-vascular 
      endothelial (VEGF(165)) and basic fibroblast (bFGF) growth factor. METHODS: We 
      enrolled 22 chronic HD patients, who were randomly assigned to either enoxaparin 
      (n=11) or UFH (n=11) anticoagulation, and followed prospectively for 12 weeks 
      before crossing over to the alternate therapy for further 12 weeks. The cytokines 
      were measured by immunoassay at the start, at 10 and 180min of HD. RESULTS: The 
      baseline VEGF(165) and bFGF levels were comparable during enoxaparin and UFH 
      treatment. VEGF(165) significantly decreased during both enoxaparin (chi(2) 
      ANOVA=33.0, P<10(-6)) and UFH (chi(2) ANOVA=27.2, P<10(-6)) anticoagulated HD, 
      while over-HD bFGF remained stable regardless of the type of heparin. The switch 
      from enoxaparin to UFH treatment was connected with 34% VEGF(165) decrease after 
      180min of HD and had no impact on bFGF. During UFH-anticoagulated HD 75% 
      VEGF(165) decrease after 10min was negatively associated with heparin dosage and 
      was more profound in patients with ischemic heart disease. CONCLUSION: The 
      traditional UFH regimen, in contrast to enoxaparin treatment, is connected with 
      dose-depended VEGF(165) decrease during HD procedure. The biological and possible 
      clinical relevance of this observation requires further investigations.
FAU - Naumnik, Beata
AU  - Naumnik B
AD  - Department of Nephrology and Transplantation with Dialysis Unit, Medical 
      University, 14 Zurawia Street, 15-540 Bialystok, Poland. bnaumnik@poczta.onet.pl
FAU - Pawlak, Krystyna
AU  - Pawlak K
FAU - Mysliwiec, Michal
AU  - Mysliwiec M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20071024
PL  - England
TA  - Cytokine
JT  - Cytokine
JID - 9005353
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*administration & dosage
MH  - Cross-Over Studies
MH  - Endothelium, Vascular/metabolism
MH  - Enoxaparin/*administration & dosage
MH  - Female
MH  - Fibroblast Growth Factor 2/*blood
MH  - Heparin/*administration & dosage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/blood/therapy
MH  - *Renal Dialysis
MH  - Time Factors
MH  - Vascular Endothelial Growth Factor A/*blood
EDAT- 2007/10/09 09:00
MHDA- 2008/03/26 09:00
CRDT- 2007/10/09 09:00
PHST- 2007/02/28 00:00 [received]
PHST- 2007/07/24 00:00 [revised]
PHST- 2007/08/13 00:00 [accepted]
PHST- 2007/10/09 09:00 [pubmed]
PHST- 2008/03/26 09:00 [medline]
PHST- 2007/10/09 09:00 [entrez]
AID - S1043-4666(07)00380-8 [pii]
AID - 10.1016/j.cyto.2007.08.011 [doi]
PST - ppublish
SO  - Cytokine. 2007 Nov;40(2):98-104. doi: 10.1016/j.cyto.2007.08.011. Epub 2007 Oct 
      24.